Global Autoimmune Treatment Market Size

Autoimmune Treatment Market Analysis

The autoimmune treatment market is expected to grow with a CAGR of 4.2%, over the forecast period (2022-2027).

The COVID-19 pandemic had an adverse effect on market growth. Patients with autoimmune rheumatic diseases are more likely to develop infections and cardiovascular co-morbidities, according to a research report released in June 2020 under the title "Challenges of autoimmune rheumatic disease therapy during the COVID-19 pandemic: A review" stated that they appear to have a slightly greater risk of acquiring severe forms rather than a clearly increased risk of COVID-19. In autoimmune rheumatic disorders, hydroxychloroquine does not show clinical COVID-19 prophylactic effectiveness. Therefore, the pandemic has had a adverse effect on how autoimmune illnesses are treated. Similarly, in January 2022, a different research study titled "Autoimmune complications of COVID-19" stated that in addition to the complications that patients experience during the COVID-19 disease period, there is growing evidence regarding the late-onset complications of COVID-19, of which autoimmune manifestations have drawn significant attention since the early months of the pandemic. The indications of COVID-19's ability to cause autoimmunity to include immunological thrombocytopenic purpura, autoimmune thyroid disorders, Kawasaki illness, Guillain-Barre syndrome, and the identification of autoantibodies. Patients with such diseases were therefore at higher risk. Thus, the pandemic had an adverse effect on market growth.

Increasing autoimmune disorders are expected to increase market growth. More than 2.8 million people worldwide, including about 1 million in the United States, are currently living with multiple sclerosis, according to the Atlas of Multiple Sclerosis Report from 2020. Autoimmune illnesses are becoming more prevalent, which is a problem for European nations. The Multiple Sclerosis Trust estimates that there are 2.5 million people worldwide who have multiple sclerosis, with Europe having the highest prevalence in 2020. Women experience multiple sclerosis more frequently than males. Women experience multiple sclerosis more frequently than males. Rheumatoid arthritis affects two million people, while psoriasis, one of the most prevalent autoimmune disorders, is thought to impact between 2% and 3% of the general population. One major factor driving rising usage rates is the increased understanding of autoimmune disorders as a result of programs for research, education, support, and activism. The American Autoimmune Related Disease Association (AARDA), which is committed to the eradication of autoimmune illnesses, the reduction of pain, and the socioeconomic impact of autoimmunity, designates the month of March each year as Autoimmune Disease Awareness Month (ADAM). The American Kidney Fund (AKF) launched a new patient-focused education and awareness campaign on lupus nephritis, a kidney condition caused by lupus, in February 2021. The AKF campaign gave lupus patients the much-needed information they need regarding the symptoms, diagnosis, and treatment of lupus nephritis. The advertising for AKF was created using grant funding from GlaxoSmithKline plc. Similarly, in September 2021, Scipher Medicine entered a partnership with Ventegra Inc. The collaboration will allow Ventegra to provide its customers with access to Scipher's PrismRA liquid molecular signature test, which aids in determining the most targeted medicine for rheumatoid arthritis patients (RA). Thus, the abovementioned factors are expected to increase market growth.

However, the higher cost of therapeutics, and low medical insurance coverage for autoimmune diseases are expected to hinder the market growth.